CIK 0001725160
- Non-accelerated filer
- Smaller reporting company
Zentalis Pharmaceuticals, Inc.
Sign in to watch- Ticker
- ZNTL
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 823607803
- Phone
- +1 858-263-4333
- Business address
- 10275 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO, CA, 92121
- Former names
- Zentalis Pharmaceuticals, LLC, Zeno Pharma, LLC
- 4 Open-market sale President sold 22,500 shares at an average $24.90 ($560,254)
- 4 Grant or award Director acquired 36,606 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- 4 Open-market sale Chief Operating Officer sold 5,000 shares at $30.00 ($150,000)
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Open-market sale Chief Operating Officer sold 5,000 shares at $30.00 ($150,000)
- 4 Open-market sale Chief Operating Officer sold 5,000 shares at an average $30.01 ($150,062)
- 4 Open-market sale Chief Operating Officer sold 25,000 shares at $30.07 ($751,653)
- 4 Grant or award Director acquired 24,871 shares (grant or award)
- 4 Grant or award Director acquired 21,817 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- 4 Grant or award President acquired 111,072 shares (grant or award)
- 4 Derivatives Options or other derivatives
- 4 Open-market sale Chief Operating Officer sold 5,000 shares at an average $30.55 ($152,745)
- 4 Open-market sale Chief Financial Officer sold 17,080 shares at an average $50.09 ($855,522)
- 4 Open-market sale President & CEO sold 20,942 shares at an average $50.01 ($1,047,317)
- 4 Open-market sale Director sold 10,000 shares at an average $50.48 ($504,769)
- 4 Open-market sale Chief Operating Officer sold 10,000 shares at an average $49.07 ($490,670)
- 4 Open-market sale Director sold 10,000 shares at an average $41.92 ($419,241)
Page 6 of 13 · 252 filings